| Literature DB >> 36232834 |
Hye-Won Na1, Hyun Soo Kim2, Hyunjung Choi1, Nari Cha1, Young Rok Seo2, Yong Deog Hong1, Hyoung-June Kim1.
Abstract
Particulate matter 2.5 (PM2.5), an atmospheric pollutant with an aerodynamic diameter of <2.5 μm, can cause serious human health problems, including skin damage. Since sebocytes are involved in the regulation of skin homeostasis, it is necessary to study the effects of PM2.5 on sebocytes. We examined the role of PM2.5 via the identification of differentially expressed genes, functional enrichment and canonical pathway analysis, upstream regulator analysis, and disease and biological function analysis through mRNA sequencing. Xenobiotic and lipid metabolism, inflammation, oxidative stress, and cell barrier damage-related pathways were enriched; additionally, PM2.5 altered steroid hormone biosynthesis and retinol metabolism-related pathways. Consequently, PM2.5 increased lipid synthesis, lipid peroxidation, inflammatory cytokine expression, and oxidative stress and altered the lipid composition and expression of factors that affect cell barriers. Furthermore, PM2.5 altered the activity of sterol regulatory element binding proteins, mitogen-activated protein kinases, transforming growth factor beta-SMAD, and forkhead box O3-mediated pathways. We also suggest that the alterations in retinol and estrogen metabolism by PM2.5 are related to the damage. These results were validated using the HairSkin® model. Thus, our results provide evidence of the harmful effects of PM2.5 on sebocytes as well as new targets for alleviating the skin damage it causes.Entities:
Keywords: human sebocytes; ingenuity pathway analysis; lipid peroxidation; particulate matter 2.5; transcriptome analysis
Mesh:
Substances:
Year: 2022 PMID: 36232834 PMCID: PMC9570376 DOI: 10.3390/ijms231911534
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1PM2.5 alters the expression of xenobiotic metabolism, inflammatory response, oxidative stress, lipid metabolism, and cell barrier-related factors. Transcriptome analysis with RNA-seq was performed using SZ95 sebocytes treated with PM2.5 (100 μg/mL) and a control group. The top 20 most prevalent KEGG terms (a) were obtained from pathway enrichment analysis of differentially expressed genes (DEGs; |fold changes| > 2, p-value < 0.05) in SZ95 sebocytes with PM2.5 treatments. Bars represent −log10 (p-value). p-values were calculated by modified Fisher’s exact tests. (b) RT-qPCR was performed to analyze the mRNA expression of DEGs. (c) The expression levels were analyzed by SDS-PAGE and immunoblotting for the indicated antibodies. The relative expression levels of proteins were quantified using the Image J program. (d) IL6 secretion was analyzed by ELISA and normalized to the total protein. Data were analyzed by Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. untreated control; n = 3).
Top canonical pathways of DEGs identified by Ingenuity Pathway Analysis (IPA). Top canonical pathways were analyzed using DEGs (|fold changes| > 1.5, p-value < 0.01). Z-score indicates the predicted activation (positive value) or inhibition (negative value) of the canonical pathway. Ratio is calculated by dividing the number of the DEGs in a pathway by the total number of genes that make up the pathway. Molecules are genes in the DEGs that are related to the pathway. p-values were calculated by right-tailed Fisher’s exact tests.
| Ingenuity Canonical Pathways | −Log | Ratio | Molecules | |
|---|---|---|---|---|
| Xenobiotic metabolism AHR signaling pathway | 6.41 | 0.23 | 3.578 | ABCG2, AHRR, ALDH1A1, ALDH1L1, ALDH3A1, ALDH3B1, ALDH3B2, ALDH6A1, CYP1A1, CYP1B1, GSTA4, GSTM2, GSTM3, GSTM4, IL1A, IL1B, IL6, UGT1A1, UGT1A3, UGT1A6 |
| Superpathway of cholesterol biosynthesis | 5.17 | 0.345 | 3.162 | ACAT2, CYP51A1, DHCR7, FDFT1, FDPS, HMGCR, HMGCS1, LSS, MSMO1, MVD |
| Cholesterol Biosynthesis I | 3.07 | 0.385 | 2.236 | CYP51A1, DHCR7, FDFT1, LSS, MSMO1 |
| Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) | 3.07 | 0.385 | 2.236 | CYP51A1, DHCR7, FDFT1, LSS, MSMO1 |
| Cholesterol Biosynthesis III (Via Desmosterol) | 3.07 | 0.385 | 2.236 | CYP51A1, DHCR7, FDFT1, LSS, MSMO1 |
| Role of IL-17A in psoriasis | 2.9 | 0.357 | −2.236 | CXCL1, CXCL6, CXCL8, S100A8, S100A9 |
| Thyroid cancer signaling | 2.4 | 0.152 | −2.887 | CCND1, CXCL8, FOS, IRS1, jun, myc, PIK3R3, RAP2B, RASD2, TCF4, TCF7L1, TP53 |
| Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via mevalonate) | 2.36 | 0.278 | 2.236 | ACAT2, FDPS, HMGCR, HMGCS1, MVD |
| Estrogen-dependent breast cancer signaling | 1.96 | 0.139 | −2.236 | AKR1C1/AKR1C2, CCND1, FOS, HSD17B1, HSD17B14, HSD17B2, HSD17B3, JUN, PIK3R3, RAP2B, RASD2 |
| eNOS signaling | 1.09 | 0.0943 | 2.496 | BDKRB1, CALML5, CAV1, CCNA1, CHRNB4, ESR2, GUCY1B1, HSPA5, KDR, LPAR1, LPAR3, PGF, PIK3R3, PRKAA2, PRKD1 |
Upstream regulators of DEGs. The top upstream regulators of DEGs (|fold changes| > 1.5, p-value < 0.01) in PM2.5 -treated SZ95 sebocytes were analyzed with IPA. Activation z-score indicates the predicted activation (positive value) or inhibition (negative value) of the upstream regulator. The p-value of overlap indicates the statistical significance of the overlap of the DEGs and genes regulated by an upstream regulator. p-values were calculated by right-tailed Fisher’s exact tests.
| Upstream Regulator | Molecule Type | Predicted Activation State | Activation | |
|---|---|---|---|---|
| SREBF1 | Transcription regulator | Activated | 4.149 | 1.11 × 10−14 |
| SREBF2 | Transcription regulator | Activated | 4.063 | 1.41 × 10−13 |
| MAPK7 | Kinase | Activated | 2.935 | 1.49 × 10−11 |
| SCAP | Other | Activated | 4.12 | 3.39 × 10−10 |
| MAP2K5 | Kinase | Activated | 3.704 | 1.59 × 10−9 |
| DSCAML1 | Other | Activated | 2.294 | 1.41 × 10−8 |
| EWSR1-FLI1 | Fusion gene/product | Activated | 2.426 | 1.72 × 10−8 |
| CYP7A1 | Enzyme | Activated | 2.333 | 3.62 × 10−7 |
| DSCAM | Other | Activated | 3.286 | 8.32 × 10−7 |
| SH3TC2 | Other | Activated | 2.111 | 1.2 × 10−6 |
| CTNNB1 | Transcription regulator | Inhibited | −2.587 | 4.66 × 10−16 |
| SMAD3 | Transcription regulator | Inhibited | −2.105 | 6.62 × 10−14 |
| WNT3A | Cytokine | Inhibited | −3.324 | 1.21 × 10−12 |
| TGFB1 | Growth factor | Inhibited | −2.179 | 3.34 × 10−12 |
| INSIG1 | Other | Inhibited | −3.761 | 4.37 × 10−11 |
| LRP6 | Transcription regulator | Inhibited | −2.619 | 1.58 × 10−9 |
| MRTFB | Transcription regulator | Inhibited | −2.939 | 8.37 × 10−9 |
| FOXO3 | Transcription regulator | Inhibited | −3.051 | 1.71 × 10−8 |
| PDGF BB | Complex | Inhibited | −2.768 | 3.16 × 10−8 |
| MFSD2A | Transporter | Inhibited | −3.293 | 3.76 × 10−8 |
Top disease and biologic functions analyzed with IPA (positive z-score value). Disease and biologic functions of DEGs (|fold changes| > 1.5, p-value < 0.01) in PM2.5-treated SZ95 sebocytes were analyzed with IPA. Z-score indicates the predicted activation (positive value) or inhibition (negative value) of the disease or function. Bias-corrected z-score is a statistically corrected value to avoid false predictions. No. of molecules is the number of genes in DEGs associated with each function. p-values were calculated by right-tailed Fisher’s exact tests and Benjamini–Hochberg correction (B–H p-value).
| Categories | Diseases or Functions | B–H | Predicted | Activation z-Score | Bias-Corrected z-Score | No. of Molecules | |
|---|---|---|---|---|---|---|---|
| Lipid metabolism, molecular transport, small molecule biochemistry | Concentration of lipid | 1.42 × 10−14 | 1.79 × 10−12 | Increased | 2.871 | 2.767 | 152 |
| dermatological diseases and conditions, organismal injury and abnormalities | Abnormality of skin morphology | 3.81 × 10−8 | 1.66 × 10−6 | Increased | 2.646 | 2.853 | 69 |
| lipid metabolism, small molecule biochemistry | Fatty acid metabolism | 6.95 × 10−15 | 9.14 × 10−13 | Increased | 2.611 | 2.078 | 111 |
| cancer, organismal injury and abnormalities, respiratory disease | Development of lung tumor | 3.6 × 10−10 | 2.3 × 10−8 | Increased | 2.566 | 2.766 | 273 |
| organismal survival | Organismal death | 1.08 × 10−17 | 1.78 × 10−15 | Increased | 2.547 | 4.19 | 380 |
Figure 2PM2.5 affects SREBP-, MAPK-, TGFβ-SMAD3-, and FoxO3a-related signaling. (a) SZ95 sebocytes were treated with PM2.5 (100 μg/mL) for 48 h. The cells were lysed with hypotonic buffer, and the cytosolic fraction and nuclei were separated. SZ95 sebocytes were treated with PM2.5 or TGFβ for the indicated times (b,c) or 48 h (d). The expression levels were analyzed by SDS-PAGE and immunoblotting for the indicated antibodies. The relative intensity of proteins was quantified using the Image J program. Data were analyzed by Student’s t-test (* p < 0.05, ** p < 0.01 vs. untreated control; n = 3).
Figure 3PM2.5 increases lipid production, ROS generation, and lipid peroxidation. SZ95 sebocytes were treated with PM2.5 (100 μg/mL). (a) Lipid production was analyzed by Bodipy 493/503 staining (green) and confocal microscopy. (b) Relative levels of major lipid classes were determined by LC–MS/MS. (c) ROS generation was analyzed by CellROX Green. (d) Lipid peroxidation was measured by DPPP staining (blue). Nuclei were stained with DAPI (blue). The fluorescence intensity was calculated using the Zen software and normalized to the DAPI fluorescence intensity (lipid production and ROS generation) or cell number (lipid peroxidation). Data were analyzed by Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. control). Original magnification: 400×. Scale bars: 20 µm.
Figure 4Immunohistochemical analysis of HairSkin®. HairSkin® was treated with PM2.5 (20 µg/ cm2) for the indicated number of days. HairSkin® sections were stained with each antibody of cytokeratin 7 (CK7), mucin 1 (MUC1), claudin1, CYP1B1, SREBP1, IL1B, and IL6. Squares marked in white represent the enlarged areas; the arrows point to representative stained regions. Original magnification: 200×. Scale bars: 200 µm.